サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：心筋梗塞治療の世界市場（2022年～2028年）
市場調査レポート
商品コード
1078187

心筋梗塞治療の世界市場（2022年～2028年）

Global Myocardial Infarction Treatment Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 125 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
心筋梗塞治療の世界市場（2022年～2028年）
出版日: 2022年04月24日
発行: Orion Market Research
ページ情報: 英文 125 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の心筋梗塞治療の市場規模は、予測期間中にCAGRで5.1%の成長が予測されています。心血管疾患の発生率の上昇と、糖分の多い食品の摂取が、予測期間中の心筋梗塞治療市場の成長に寄与しています。

当レポートでは、世界の心筋梗塞治療市場について調査分析し、市場概要、競合情勢、セグメント分析、地域分析などを提供しています。

目次

第1章 レポートサマリー

第2章 市場概要と考察

  • 調査範囲
  • アナリストの考察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
  • Bayer AG
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の発展
  • GlaxoSmithKline PLC
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の発展
  • Novartis AG
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の発展
  • Pfizer Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の発展
  • Teva Pharmaceutical Industries Ltd.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の発展
  • 主要戦略分析
  • 主要企業に対するCOVID-19の影響

第4章 市場セグメンテーション

  • 世界の心筋梗塞治療市場：タイプ別
    • ST上昇型心筋梗塞（STEMI）心臓発作
    • 非ST上昇型心筋梗塞（NSTEMI）心臓発作
    • サイレント心臓発作
  • 世界の心筋梗塞治療市場：装置別
    • 左心室補助装置
    • ペースメーカー
    • 植込み型除細動器
    • その他（吸引ベースのカテーテル）
  • 世界の心筋梗塞治療市場：診断別
    • 心電図検査（ECG）
    • 胸部X線
    • コンピュータ断層撮影（CTスキャン）
    • 心エコー検査
    • その他（血液検査）
  • 世界の心筋梗塞治療市場：治療別
    • 投薬
    • 手術
  • 世界の心筋梗塞治療市場：エンドユーザー別
    • 病院・診療所
    • 外来手術センター
    • 研究機関

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • その他の地域

第6章 企業プロファイル

  • Abliva AB
  • advanceCOR GmbH
  • AstraZeneca
  • Athersys, Inc.
  • BioVascular Inc.
  • Boehringer Ingelheim International GmbH.
  • Bristol Myers Squibb (BMS)
  • Caladrius Biosciences, Inc.
  • Capricor Therapeutics
  • CSL Behring LLC
  • Egetis Therapeutics AB
  • GNT Pharma Co., Ltd
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Mesoblast Ltd.
  • Osiris Therapeutics, Inc.
  • Sandoz International GmbH
  • Sanofi
  • Viatris Inc.
図表

LIST OF TABLES

  • 1. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBALSTEMI HEART ATTACKSMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBALNSTEMI HEART ATTACKSMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBALSILENT HEART ATTACKSMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICE, 2021-2028 ($ MILLION)
  • 6. GLOBALLEFT VENTRICULAR ASSIST DEVICE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBALPACEMAKER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBALIMPLANTABLE CARDIOVERTER DEFIBRILLATORMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBALOTHERMYOCARDIAL INFARCTION TREATMENT DEVICESMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 11. GLOBALMYOCARDIAL INFARCTION TREATMENT BY ELECTROCARDIOGRAPHY (ECG)MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBALMYOCARDIAL INFARCTION TREATMENT BY CHEST X-RAYMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBALMYOCARDIAL INFARCTION TREATMENT BY COMPUTED TOMOGRAPHY (CT SCAN) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBALMYOCARDIAL INFARCTION TREATMENT BY ECHOCARDIOGRAPHYMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBALOTHER MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 16. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 17. GLOBALMYOCARDIAL INFARCTION MEDICATION TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 18. GLOBALMYOCARDIAL INFARCTION SURGERY TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 19. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 20. GLOBALHOSPITAL & CLINICSMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 21. GLOBALAMBULATORY SURGICAL CENTERSMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 22. GLOBALRESEARCH INSTITUTESMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 23. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 24. NORTH AMERICAN MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 25. NORTH AMERICAN MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 26. NORTH AMERICAN MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICE, 2021-2028 ($ MILLION)
  • 27. NORTH AMERICAN MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 28. NORTH AMERICAN MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 29. NORTH AMERICAN MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 30. EUROPEAN MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 31. EUROPEAN MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 32. EUROPEAN MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICE, 2021-2028 ($ MILLION)
  • 33. EUROPEAN MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 34. EUROPEAN MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 35. EUROPEAN MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 36. ASIA-PACIFIC MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 37. ASIA-PACIFIC MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 38. ASIA-PACIFIC MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICE, 2021-2028 ($ MILLION)
  • 39. ASIA-PACIFIC MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 40. ASIA-PACIFIC MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 41. ASIA-PACIFIC MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 42. REST OF THE WORLD MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 43. REST OF THE WORLD MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 44. REST OF THE WORLD MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICE, 2021-2028 ($ MILLION)
  • 45. REST OF THE WORLD MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
  • 46. REST OF THE WORLD MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
  • 47. REST OF THE WORLD MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET, 2022-2028 (%)
  • 4. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL STEMI HEART ATTACKSMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL MYOCARDIAL INFARCTION TREATMENT FROM NSTEMI HEART ATTACKSMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL MYOCARDIAL INFARCTION TREATMENT FROM SILENT HEART ATTACKSMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET SHARE BY DEVICE, 2021 VS 2028 (%)
  • 9. GLOBAL LEFT VENTRICULAR ASSIST DEVICEMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL PACEMAKERMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL OTHERMYOCARDIAL INFARCTION TREATMENT DEVICES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET SHARE BY DIAGNOSIS, 2021 VS 2028 (%)
  • 14. GLOBAL MYOCARDIAL INFARCTION TREATMENT BY ELECTROCARDIOGRAPHY (ECG)MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. GLOBAL MYOCARDIAL INFARCTION TREATMENT BY CHEST X-RAYMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. GLOBAL MYOCARDIAL INFARCTION TREATMENT BY COMPUTED TOMOGRAPHY (CT SCAN)MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 17. GLOBAL MYOCARDIAL INFARCTION TREATMENT BY ECHOCARDIOGRAPHYMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 18. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET SHARE BY TREATMENT, 2021 VS 2028 (%)
  • 19. GLOBAL MYOCARDIAL INFARCTION MEDICATION TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 20. GLOBAL MYOCARDIAL INFARCTION SURGERY TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 21. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET SHARE BY END-USER, 2021 VS 2028 (%)
  • 22. GLOBAL HOSPITAL & CLINICSMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 23. GLOBAL AMBULATORY SURGICAL CENTERSMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 24. GLOBAL RESEARCH INSTITUTESMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 25. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 26. US MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. CANADA MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. UK MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. FRANCE MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. GERMANY MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 31. ITALY MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 32. SPAIN MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 33. REST OF EUROPE MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 34. INDIA MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 35. CHINA MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 36. JAPAN MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 37. SOUTH KOREA MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 38. REST OF ASIA-PACIFIC MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 39. REST OF THE WORLD MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2019522

Global Myocardial Infarction TreatmentMarket Size, Share & Trends Analysis Report byType (ST segment elevation myocardial infarction (STEMI) Heart Attacks, Non-ST segment elevation myocardial infarction (NSTEMI) Heart Attacks, and Silent Heart Attacks), by Device (Left Ventricular Assist Device, Pacemaker, Implantable Cardioverter Defibrillator, and Others), by Diagnosis (Electrocardiography (ECG), Chest X-Ray, Computed Tomography (CT Scan), Echocardiography, and Others), by Treatment (Medication andSurgery), and by End-User(Hospital & Clinics, Ambulatory Surgical Centers, and Research Institutes) Forecast (2022-2028)

The global myocardial infarction treatment market is anticipated to grow at a considerable CAGR of 5.1% during the forecast period.Rising incidence rate of CVDs (cardiovascular diseases) and intake of high-level sugary food contributes to the growth of the myocardial infarction market during the forecast period. According to WHO,CVDs are the leading cause of death globally, taking an estimated 17.9 million lives each year. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.

The high cost of myocardial infarction treatment and delay in certification for heart treatment are some factors restraining the growth of the market. However, the supportive laws and schemes for the reduction and prevention of heart diseases and the rising adoption of minimally invasive treatment are anticipated to create the future opportunity for the growth of the myocardial infarction market.

The global myocardial infarction treatment market is segmented based on the type, device, diagnosis, treatment, and end-user. Based on the type, the market is sub-segmented into ST segment elevation myocardial infarction (STEMI) heart attacks, non-ST segment elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on, the device, the market is sub-segmented into the left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others. Based on, the diagnosis, the market is sub-segmented into the electrocardiography (ECG), chest x-ray, computed tomography (CT scan), echocardiography, and others. Based on, the treatment, the market is sub-segmented into the medication and surgery. Further, on the basis of end-user, the market is sub-segmented into hospital & clinics, ambulatory surgical centers, and research institutes. On the basis of

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.Europe is the second largest market for myocardial infarction treatment across the globe, owing to favorable reimbursement policies and supportive laws and schemes for healthcare technology are some of the major factors fuelling the growth of the market in the region.Growing healthcare spending and improving healthcare system is another factor contributing to the growth of myocardial infarction treatment market during the forecast period in European region. According to the European Union Healthcare expenditure was highest among the EU Member States in Luxembourg (EUR 5 502 per inhabitant), Denmark (EUR 5 355 per inhabitant) and Sweden (EUR 5 042 per inhabitant) in 2019.

The major companies serving the global myocardial infarction treatment market include Bayer AG, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market.

Research Methodology

The market study of the global myocardial infarction treatment marketis incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Myocardial Infarction Treatment Market Research and Analysis by Type.

2. Global Myocardial Infarction Treatment Market Research and Analysis by Devices.

3. Global Myocardial Infarction Treatment Market Research and Analysis by Diagnosis.

4. Global Myocardial Infarction Treatment Market Research and Analysis by Treatment.

5. Global Myocardial Infarction Treatment Market Research and Analysis by End-Users.

The Report Covers

  • Comprehensive research methodology of the global myocardial infarction treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global myocardial infarction treatment market.
  • Insights about market determinants that are stimulating the global myocardial infarction treatment market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

Category- Medical Devices

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Myocardial Infarction Treatment Market
  • Recovery Scenario of Global Myocardial Infarction Treatment Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Bayer AG
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. GlaxoSmithKline PLC
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Novartis AG
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Pfizer Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Teva Pharmaceutical Industries Ltd.
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis
  • 3.8. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Myocardial Infarction Treatment Market by Type
    • 4.1.1. ST segment elevation myocardial infarction (STEMI) Heart Attacks
    • 4.1.2. Non-ST segment elevation myocardial infarction (NSTEMI) Heart Attacks
    • 4.1.3. Silent Heart Attacks
  • 4.2. Global Myocardial Infarction Treatment Market by Device
    • 4.2.1. Left Ventricular Assist Device
    • 4.2.2. Pacemaker
    • 4.2.3. Implantable Cardioverter Defibrillator
    • 4.2.4. Others (Aspiration-Based Catheters)
  • 4.3. Global Myocardial Infarction Treatment Market by Diagnosis
    • 4.3.1. Electrocardiography (ECG)
    • 4.3.2. Chest X-Ray
    • 4.3.3. Computed Tomography (CT Scan)
    • 4.3.4. Echocardiography
    • 4.3.5. Others (Blood Test)
  • 4.4. Global Myocardial Infarction Treatment Market by Treatment
    • 4.4.1. Medication
      • 4.4.1.1. Analgesics
      • 4.4.1.2. Thrombolytic
      • 4.4.1.3. Antiplatelet Agents
      • 4.4.1.4. Glycoprotein IIb/IIIa Inhibitors
      • 4.4.1.5. Others (Adrenergic Blockers)
    • 4.4.2. Surgery
      • 4.4.2.1. Angioplasty
      • 4.4.2.2. Bypass Surgery
      • 4.4.2.3. Heart Transplant
  • 4.5. Global Myocardial Infarction Treatment Market by End-Users
    • 4.5.1. Hospital & Clinics
    • 4.5.2. Ambulatory Surgical Centers
    • 4.5.3. Research Institutes

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abliva AB
  • 6.2. advanceCOR GmbH
  • 6.3. AstraZeneca
  • 6.4. Athersys, Inc.
  • 6.5. BioVascular Inc.
  • 6.6. Boehringer Ingelheim International GmbH.
  • 6.7. Bristol Myers Squibb (BMS)
  • 6.8. Caladrius Biosciences, Inc.
  • 6.9. Capricor Therapeutics
  • 6.10. CSL Behring LLC
  • 6.11. Egetis Therapeutics AB
  • 6.12. GNT Pharma Co., Ltd
  • 6.13. Johnson & Johnson Services, Inc.
  • 6.14. Merck KGaA
  • 6.15. Mesoblast Ltd.
  • 6.16. Osiris Therapeutics, Inc.
  • 6.17. Sandoz International GmbH
  • 6.18. Sanofi
  • 6.19. Viatris Inc.